Core Insights - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers through the inhibition of GSK-3β [1][4] - The company will present data on its investigational drug elraglusib for advanced salivary gland carcinoma at the AACR Annual Meeting 2025 [1][2] - Elraglusib is being studied in combination with chemotherapy and immunotherapy, showing promising response rates in specific cancer populations [2][4] Presentation Details - The poster presentation titled "Elraglusib, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancer" will take place on April 29, 2025 [2] - An independent research group will also present findings on the synergistic effects of elraglusib in combination with investigational compounds from Jazz Pharmaceuticals [3] Company Overview - Actuate's lead drug, elraglusib, targets molecular pathways that promote tumor growth and resistance to conventional therapies, potentially enhancing anti-tumor immunity [4]
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025